A pharmaceutical representative comes to your office and tells you that although macitentan is expensive ($7,337 for 30 10 mg tablets), treatment reduced the risk of trial endpoints ("All events related to PAH or death in table above) by 32% so the number needed to treat is not very high. Do you agree? (Note: Only the 10 mg dose of macitentan is available for prescription).
I was confused about the number 32%, is it a relative risk reduction or absolute risk reduction?
Thank you very much.
Thongchai